{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:12:05Z","timestamp":1789506725733,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128863","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:23:42Z","timestamp":1782347022000},"page":"128863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Safety and immunogenicity of a genetically inactivated stand-alone acellular pertussis vaccine as a booster to Australian adults: a randomized, controlled, non-inferiority trial"],"prefix":"10.1016","volume":"88","author":[{"given":"Madeline M.","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita H.J.","family":"van den Biggelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Librada","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilasinee","family":"Yuwaree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chawanee","family":"Kerdsomboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souad","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pham Hong","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ushma","family":"Wadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2026.128863_bb0005","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.EI10-0008-2015","article-title":"Bordetella pertussis","volume":"4","author":"Nieves","year":"2016","journal-title":"Microbiol Spectr"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128863_bb0010","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1473-3099(02)00452-8","article-title":"Pertussis of adults and infants","volume":"2","author":"von Konig","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128863_bb0015","series-title":"Stay safe from whooping cough this holiday season","author":"Australian Centre for Disease Control","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128863_bb0020","series-title":"National Notifiable Disease Surveillance System, Department of Health and Aged Care, Editor","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128863_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01344","article-title":"Pertussis prevention: reasons for resurgence, and differences in the current acellular pertussis vaccines","volume":"10","author":"Esposito","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128863_bb0035","article-title":"Evaluation of whole-cell and acellular pertussis vaccines in the context of long-term herd immunity","volume":"11","author":"Szwejser-Zawislak","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128863_bb0040","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1586\/14760584.2015.1059759","article-title":"Changing from whole-cell to acellular pertussis vaccines would trade superior tolerability for inferior protection","volume":"14","author":"Herzog","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128863_bb0045","doi-asserted-by":"crossref","first-page":"e20153326","DOI":"10.1542\/peds.2015-3326","article-title":"Waning Tdap effectiveness in adolescents","volume":"137","author":"Klein","year":"2016","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128863_bb0050","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1586\/14760584.2014.944167","article-title":"Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology","volume":"13","author":"Sheridan","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"51","key":"10.1016\/j.vaccine.2026.128863_bb0055","doi-asserted-by":"crossref","first-page":"8194","DOI":"10.1016\/j.vaccine.2020.10.070","volume":"38","author":"Fortuna","year":"2020","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128863_bb0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0264-410X(95)00230-X","article-title":"The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies","volume":"14","author":"Ibsen","year":"1996","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128863_bb0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/21645515.2017.1385686","article-title":"A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults","volume":"14","author":"Leroux-Roels","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128863_bb0075","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2180-12-61","article-title":"Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated pertussis toxin and pertactin by unmarked allelic exchange","volume":"12","author":"Buasri","year":"2012","journal-title":"BMC Microbiol"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128863_bb0085","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S1473-3099(18)30375-X","article-title":"Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2\/3 randomised, controlled, non-inferiority trial","volume":"18","author":"Pitisuttithum","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128863_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100976","article-title":"Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP(gen) or combined TdaP(gen) vaccines","volume":"37","author":"Pitisuttithum","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128863_bb0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.49182","article-title":"Pertussis immunity 5 years after booster vaccination with recombinant pertussis vaccines","volume":"7","author":"Pitisuttithum","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128863_bb0100","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/cid\/ciy594","article-title":"Boosting teenagers with acellular pertussis vaccines containing recombinant or chemically inactivated pertussis toxin: a randomized clinical trial","volume":"68","author":"Blanchard Rohner","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128863_bb0105","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.vaccine.2021.10.076","article-title":"A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age","volume":"40","author":"Chokephaibulkit","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128863_bb0110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1473-3099(17)30612-6","article-title":"A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2\/3, randomised controlled non-inferiority trial","volume":"18","author":"Sricharoenchai","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128863_bb0115","series-title":"Recommendations to assure the quality, safety and efficacy of acellular pertussis vaccines, annex 4, TRS No 979","author":"Organisation","year":"2014"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128863_bb0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0092-1157(85)80034-2","article-title":"The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells","volume":"13","author":"Gillenius","year":"1985","journal-title":"J Biol Stand"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128863_bb0125","first-page":"222","article-title":"Points to consider on switching between superiority and non-inferiority","volume":"52","author":"EMA Committee for Proprietary Medicinal Products","year":"2026","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128863_bb0130","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1086\/315318","article-title":"Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis","volume":"181","author":"Taranger","year":"2000","journal-title":"J Infect Dis"},{"issue":"20","key":"10.1016\/j.vaccine.2026.128863_bb0135","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0264-410X(98)00227-8","article-title":"Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis","volume":"16","author":"Storsaeter","year":"1998","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2026.128863_bb0140","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/S0264-410X(98)00226-6","article-title":"A search for serologic correlates of immunity to Bordetella pertussis cough illnesses","volume":"16","author":"Cherry","year":"1998","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128863_bb0145","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0264-410X(93)90286-7","article-title":"Serological correlates in whooping cough","volume":"11","author":"Granstrom","year":"1993","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128863_bb0150","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0264-410X(92)90002-2","article-title":"Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance","volume":"10","author":"Storsaeter","year":"1992","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128863_bb0160","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/INF.0000000000001767","article-title":"Is there a need for a stand-alone acellular pertussis vaccine?","volume":"37","author":"Heininger","year":"2018","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128863_bb0165","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41467-024-44943-7","article-title":"Maternal pertussis immunization and the blunting of routine vaccine effectiveness: a meta-analysis and modeling study","volume":"15","author":"Briga","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128863_bb0170","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12916-021-02005-5","article-title":"A phase IV, multi-Centre, randomized clinical trial comparing two pertussis-containing vaccines in pregnant women in England and vaccine responses in their infants","volume":"19","author":"Jones","year":"2021","journal-title":"BMC Med"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128863_bb0175","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.vaccine.2019.10.104","article-title":"Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial","volume":"38","author":"Perrett","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128863_bb0180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eclinm.2019.06.010","article-title":"The effect of maternal immunisation during pregnancy on infant vaccine responses","volume":"13","author":"Zimmermann","year":"2019","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128863_bb0185","doi-asserted-by":"crossref","first-page":"e1087","DOI":"10.1093\/cid\/ciac432","article-title":"Maternal tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccination during pregnancy: impact on infant anti-pertussis antibody concentrations by maternal pertussis priming series","volume":"76","author":"Havers","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128863_bb0190","series-title":"Real-world effectiveness of maternal genetically inactivated acellular pertussis vaccination in protecting infants under three months of age","author":"Phiriyasart","year":"2026"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26006729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26006729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:46:36Z","timestamp":1789505196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26006729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"alternative-id":["S0264410X26006729"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128863","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a genetically inactivated stand-alone acellular pertussis vaccine as a booster to Australian adults: a randomized, controlled, non-inferiority trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128863"}}